CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

CureVac ( (CVAC)) has issued an update. CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline in ...

Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The global downstream processing market size was US$ 23.8 billion in 2021. The global downstream processing market is projected to grow to US$ 89.1 billion by 2030 by registering a compound annual ...

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight ...

Eli Lilly has been accused of giving illegal inducements to encourage medical providers in Texas to prescribe its medicines ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Promising Adenoid Cystic Carcinoma Pipeline Therapies such as CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.